Haploidentical donor the donor of choice in the treatment of relapse Hodgkin’s lymphoma
| Autor: | Marija Elez, Milena Todorovic-Balint |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Medical review. 75:54-56 |
| ISSN: | 1820-7383 0025-8105 |
| Popis: | Introduction. Modern treatment of Hodgkin?s lymphoma has led to a cure in 60-90% of patients. The problem are patients in whom disease relapse occurs, or the disease is refractory to initial therapy. The standard relapse treatment is the application of high-dose chemotherapy with autologous stem cell transplantation. However, about half of patients experience treatment failure after autologous stem cell transplantation. Despite the application of new therapeutic modalities, the disease relapses, so allogeneic stem cell transplantation is the method of choice in further treatment. Haploidentical transplantation - yes/no. The donor for an allogeneic transplant can be related or unrelated to human leukocyte associated antigen-matched or haploidentical related. Allogeneic transplantation is used in Hodgkin?s lymphoma because of the strong effect of the graft against lymphoma. The dilemmas of whether a haploidentical donor compared to a related/unrelated matched donor are better and when treating of Hodgkin?s lymphoma with allogeneic stem cell transplantation are presented in this paper. Conclusion. Allogeneic transplantation is still the only potentially curative therapeutic option to treat Hodgkin?s lymphoma. In order for the treatment outcome to be as good as possible, it is necessary to precisely define the pre-transplant conditioning, as well as the selection of the donor. Randomized multicenter studies provide answers to all doubts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|